Lv2
180 积分 2025-02-14 加入
Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial
2个月前
已完结
Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials
2个月前
已完结
Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials
2个月前
已完结
Neutrophil extracellular traps, B cells, and type I interferons contribute to immune dysregulation in hidradenitis suppurativa
2个月前
已完结
Diagnosis and treatment of acne inversa/hidradenitis suppurativa in China: an expert consensus statement （2021 version）
2个月前
已完结
Diagnosis and Treatment Options for T2-Low Asthma
4个月前
已完结
[2024 Chinese guidelines for the diagnosis and treatment of rheumatoid arthritis]
4个月前
已完结
嗜酸性肉芽肿性多血管炎诊治多学科专家共识（2025年版）
6个月前
已完结
Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype
7个月前
已完结
Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype
7个月前
已完结
皖公网安备34019202002308
